Your browser doesn't support javascript.
loading
Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines.
Aydillo, Teresa; Balsera-Manzanero, Maria; Rojo-Fernandez, Amaya; Escalera, Alba; Salamanca-Rivera, Celia; Pachón, Jerónimo; Del Mar Muñoz-García, María; Sánchez-Cordero, María José; Sánchez-Céspedes, Javier; García-Sastre, Adolfo; Cordero, Elisa.
Afiliación
  • Aydillo T; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Balsera-Manzanero M; Icahn School of Medicine at Mount Sinai, Global Health and Emerging Pathogens Institute, New York, USA.
  • Rojo-Fernandez A; Viral Diseases and Infections in Immunodeficiencies Research Group, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
  • Escalera A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Salamanca-Rivera C; Icahn School of Medicine at Mount Sinai, Global Health and Emerging Pathogens Institute, New York, USA.
  • Pachón J; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Del Mar Muñoz-García M; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, USA.
  • Sánchez-Cordero MJ; Unit of Infectious Diseases, Microbiology and Parasitology, Virgen del Rocío University Hospital, Sevilla, Spain.
  • Sánchez-Céspedes J; Department of Preventive Medicine, University of Seville, Spain.
  • García-Sastre A; Viral Diseases and Infections in Immunodeficiencies Research Group, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital/CSIC/University of Seville, Seville, Spain.
  • Cordero E; Department of Medicine, School of Medicine, University of Sevilla, Sevilla, Spain.
Emerg Microbes Infect ; 13(1): 2292068, 2024 Dec.
Article en En | MEDLINE | ID: mdl-38054302
ABSTRACT
Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 antigens is unknown. We aimed to understand the impact of mRNA COVID-19 vaccines administered concomitantly on the immune response to influenza vaccines. For this, 128 volunteers were vaccinated during the 22-23 influenza season. Three groups of vaccination were assembled FLU vaccine only (46, 35%) versus volunteers that received the mRNA bivalent COVID-19 vaccines concomitantly to seasonal influenza vaccines, FluCOVID vaccine in the same arm (42, 33%) or different arm (40, 31%), respectively. Sera and whole blood were obtained the day of vaccination, +7, and +28 days after for antibody and T cells response quantification. As expected, side effects were increased in individuals who received the FluCOVID vaccine as compared to FLU vaccine only based on the known reactogenicity of mRNA vaccines. In general, antibody levels were high at 4 weeks post-vaccination and differences were found only for the H3N2 virus when administered in different arms compared to the other groups at day 28 post-vaccination. Additionally, our data showed that subjects that received the FluCOVID vaccine in different arm tended to have better antibody induction than those receiving FLU vaccines for H3N2 virus in the absence of pre-existing immunity. Furthermore, no notable differences in the influenza-specific cellular immune response were found for any of the vaccination groups. Our data supports the concomitant administration of seasonal influenza and mRNA COVID-19 vaccines.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: Emerg Microbes Infect Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / Vacunas contra la COVID-19 / COVID-19 Límite: Humans Idioma: En Revista: Emerg Microbes Infect Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos